About Adaptimmune

Leading the TCR T-cell therapy space

Leading the TCR T-cell therapy space

Transforming cancer immunotherapy with affinity enhanced T-cell receptors

Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.

We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells.

Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of its business.

Company History


Responses in six solid tumor indications 

Complete response in first patient treated with ADP-A2AFP in Cohort 3

Partnership with Astellas to develop allogeneic cell therapies 

~$90M raised via secondary public offering in January

~$240M raised via public offering in June


Responses with ADP-A2M4 in synovial sarcoma and antitumor activity in other solid tumors with ADP-A2M4, ADP-A2M10, ADP-A2AFP

SPEARHEAD-1 trial started 2H19 (synovial sarcoma and myxoid/round cell liposarcoma [MRCLS])

SURPASS (first next-gen candidate) started 2H19

Collaboration with Alpine Immune Sciences

Agreement with Noile-Immune Biotech


Registered Direct Offering (RDO) of ~$100M

Transition of NY-ESO SPEAR T-cell Therapy Program to GSK complete
gsk logo

Opening of UK Vector Manufacturing Facility at Catapult in Stevenage


Option exercise by GSK for exclusive license to NY-ESO SPEAR T-cell program

Completion of public offering with net proceeds of $61,397,000


Breakthrough therapy designation and PRIME regulatory access for NY-ESO SPEAR T-cell therapy

*NY-ESO program was transitioned to GSK in August 2018


Adaptimmune IPO on NASDAQ raises $176M.


TCR technology developed at Oxford University

Avidex was formed on the basis of T-cell receptor technology from Oxford University

Avidex was acquired by Medigene

Adaptimmune spun out as a virtual company with University of Penn collaboration

Adaptimmune establishes R&D infrastructure and delivers promising clinical data

Strategic collaboration with GSK + $104M Series A Funding Round


Read perspectives from our colleagues and external experts on our work and how we are improving cancer patients’ lives.

Our Perspectives